Irbesartan/Hidroclorotiazida Tarbis (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This results in relaxed blood vessels and reduced sodium and water retention, which together lower blood pressure.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s condition, response to therapy, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The product is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless clearly needed. Safety during breastfeeding has not been established, so a healthcare provider should be consulted before use in nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Irbesartan/Hidroclorotiazida combines an ARB with a thiazide diuretic, offering dual mechanisms—vascular relaxation and diuresis. Compared with monotherapy ARBs or ACE inhibitors, the combination often provides greater blood‑pressure reduction, especially in patients who need additional volume control, while maintaining a convenient single‑tablet regimen.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include severe hypotension, hyperkalemia, acute kidney injury, and allergic reactions such as angioedema. Patients should be monitored for signs of these conditions, especially during the initial treatment period or when other interacting drugs are used.

The combination should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in individuals with severe renal impairment, hyperkalemia, or those who are pregnant. Clinicians must assess each patient’s medical history before prescribing.